Fig. 7

Glibenclamide and Abcc8−/− protect against axonal damage. a–d White matter of lumbar spinal cord sections from WT control (a), untreated pid-30 WT/EAE (b), glibenclamide-treated pid-30 WT/EAE (c), and pid-30 Abcc8−/−/EAE (d) mice, immunolabeled for SMI-312 (neurofilament marker) or stained with silver nitrate, as indicated; original magnification, ×400. e Percent of quadrants with axonal loss by SMI-132 labeling and by silver nitrate staining; four mice/group; ^## P < 0.01 and ^### P < 0.001 with respect to WT control; ***P < 0.001 with respect to WT/EAE; scale bars, 100 μm